| # | Title | Journal | Year | Citations |
|---|
| 1 | Incidence of soft tissue sarcoma and beyond | Cancer | 2012 | 210 |
| 2 | Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study | Annals of Oncology | 2015 | 113 |
| 3 | Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial | Lancet Oncology, The | 2021 | 95 |
| 4 | Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET) | Annals of Oncology | 2013 | 61 |
| 5 | Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions | BMC Health Services Research | 2012 | 57 |
| 6 | Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy | Annals of Oncology | 2015 | 54 |
| 7 | Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma | Anti-Cancer Drugs | 2012 | 42 |
| 8 | Nonoperative Management of Squamous-Cell Carcinoma of the Rectum | Diseases of the Colon and Rectum | 2015 | 34 |
| 9 | Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas | Journal of the National Cancer Institute | 2017 | 28 |
| 10 | Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients | Oncotarget | 2016 | 26 |
| 11 | Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response | British Journal of Cancer | 2018 | 23 |
| 12 | A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin α: a prospective randomized controlled trial of the ELYPSE study group | Annals of Oncology | 2009 | 20 |
| 13 | An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents | BMC Cancer | 2014 | 15 |
| 14 | Adhesion to Clinical Practices Guidelines (CPG'S) and Role on Survival for Soft Tissue Sarcoma Patients. Analysis of a Population Based Cohort from Rhone-Alpes Region | Annals of Oncology | 2012 | 12 |
| 15 | Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma | Anti-Cancer Drugs | 2012 | 10 |
| 16 | Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool | BMC Health Services Research | 2014 | 9 |
| 17 | Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME | Cancer Medicine | 2021 | 5 |
| 18 | Phase I Study of Daily Irinotecan as a Radiation Sensitizer for Locally Advanced Pancreatic Cancer | International Journal of Radiation Oncology Biology Physics | 2010 | 2 |
| 19 | Immunotherapy in head and neck cancer | Anti-Cancer Drugs | 2018 | 0 |
| 20 | External validation of a prognostic score in patients (pts) with high-grade gastrointestinal neuroendocrine carcinomas (GI-NECs). | Journal of Clinical Oncology | 2016 | 0 |
| 21 | REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. | Journal of Clinical Oncology | 2016 | 0 |
| 22 | Comparison of BEAMing assays and competitive approaches in the detection of main alteration of RAS in circulating DNA of non small-cell lung cancer (NSCLC) and metastatic colon cancer. Manuscript 2016. | Journal of Clinical Oncology | 2017 | 0 |
